An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement

Canadian Journal of Hospital Pharmacy

Volumn 55, Issue 2, 2002, Pages 128-135

  Friesen, Erwin ^a   Lier, Doug ^a   Bachynsky, John ^a   Jacobs, Philip ^a  

^a Health Economics Research Centre   (Canada)

Author keywords

Cost analysis; Deep vein thrombosis; Enoxaparin; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; DEXTRAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HIP ARTHROPLASTY; HOSPITAL COST; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NURSING; POSTOPERATIVE CARE; WORKLOAD;

EID: 0036257053     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement
2. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo
3. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
4. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
5. Low molecular weight heparin: A critical analysis of clinical trials
6. Cost-effectiveness of the prevention of deep-vein thrombosis and pulmonary embolism
7. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
8. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty
9. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty
10. Fundamentals of clinical trials
11. A comparison of work- load estimates using three methods of patient classification
12. Elements of econometrics
13. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation
14. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty